Oncopeptides AB (publ) (FRA:OND)

Germany · Delayed Price · Currency is EUR

0.454

-0.034 (-6.97%)

Last updated: Dec 4, 2025, 8:34 AM CET

245.13% (1Y)

Market Cap	133.15M
Revenue (ttm)	5.65M
Net Income (ttm)	-24.23M
Shares Out	n/a
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,184
Open	0.454
Previous Close	0.488
Day's Range	0.454 - 0.454
52-Week Range	0.111 - 0.596
Beta	n/a
RSI	48.70
Earnings Date	Feb 27, 2026

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hyd... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2000

Employees 80

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol OND

Full Company Profile

Financial Performance

In 2024, Oncopeptides AB's revenue was 31.65 million, a decrease of -10.14% compared to the previous year's 35.22 million. Losses were -284.61 million, 14.2% more than in 2023.

Financial numbers in SEK Financial Statements

News

There is no news available yet.